This database contains 457 studies, archived under the term: "drug therapy"
Click here to filter this large number of results.
Long-term safety and efficacy of donepezil in patients with dementia with Lewy bodies: results from a 52-week, open-label, multicenter extension study
Ikeda, Manabu,
Mori, Etsuro,
Kosaka, Kenji,
Iseki, Eizo,
Hashimoto, Mamoru,
Matsukawa, Noriyuki,
Matsuo, Kazutaka,
Nakagawa, Masaki
Background/aims: To investigate the safety and efficacy of long-term administration (52 weeks) of donepezil in patients with dementia with Lewy bodies (DLB).; Methods: This was a 52-week, multicenter, open-label extension study. Up to 8 weeks after the completion of the preceding randomized, placebo-controlled trial (RCT), patients started treatment with 3 mg of donepezil daily for […]
Cilostazol add-on therapy in patients with mild dementia receiving donepezil: A retrospective study
Ihara, Masafumi,
Nishino, Madoka,
Taguchi, Akihiko,
Yamamoto, Yumi,
Hattori, Yorito,
Saito, Satoshi,
Takahashi, Yukako,
Tsuji, Masahiro,
Kasahara, Yukiko,
Takata, Yu,
Okada, Masahiro
Goal: Combinatorial therapy directed at both vascular and neurodegenerative aspects of dementia may offer a promising strategy for treatment of dementia, which often has a multifactorial basis in the elderly. We investigated whether the phosphodiesterase III inhibitor cilostazol, which is often used in the prevention of stroke and peripheral artery disease, may delay cognitive decline […]
Long-term statin therapy is associated with better episodic memory in aged familial hypercholesterolemia patients in comparison with population controls
Hyttinen, Laura,
TuulioHenriksson, Annamari,
Vuorio, Alpo F.,
Kuosmanen, Noora,
Härkänen, Tommi,
Koskinen, Seppo,
Strandberg, Timo E.
The cognitive status of aged familial hypercholesterolemia (FH) patients treated with long-term statin therapy was compared with that of population controls. A comprehensive cohort of 43 elderly (age > or = 65 years) patients all with the same FH North Karelia mutation living in North Karelia (eastern Finland) was identified, 37 of whom (aged 65 […]
Safety, tolerability, and efficacy of PBT2 in Huntington’s disease: A phase 2, randomised, double-blind, placebo-controlled trial
Background: PBT2 is a metal protein-attenuating compound that might reduce metal-induced aggregation of mutant huntingtin and has prolonged survival in a mouse model of Huntington’s disease. We aimed to assess the safety, tolerability, and efficacy of PBT2 in patients with Huntington’s disease. Methods: In this 26-week, randomised, double-blind, placebo-controlled trial, adults (≥ 25 years old) […]
Memantine effects measured with the Relevant Outcome Scale for Alzheimer’s disease in an open-label, single-arm, multicenter clinical study
Holthoff, Vjera,
Ferris, Steven,
Gauthier, Serge,
Ihl, Ralf,
Robert, Philippe,
Winblad, Bengt,
Sternberg, Kati,
Tennigkeit, Frank
Objective: The Relevant Outcome Scale for Alzheimer’s disease (ROSA) is a novel, valid, and reliable instrument for multidimensional assessment of Alzheimer’s disease (AD) symptoms across all severity stages. The ROSA and four standard instruments — the Alzheimer’s disease Assessment Scale-cognitive (ADAS-cog), Severe Impairment Battery (SIB), Disability Assessment for Dementia (DAD), and the Neuropsychiatric Inventory (NPI) […]
Antihypertensive therapy and cerebral hemodynamics in executive mild cognitive impairment: results of a pilot randomized clinical trial
Hajjar, Ihab,
Hart, Meaghan,
Chen, Yu-Ling,
Mack, Wendy,
Novak, Vera,
C. Chui, Helena,
Lipsitz, Lewis
Objectives: To compare the effects of three antihypertensive medications on cerebral hemodynamic and cognitive function in hypertensive individuals with executive dysfunction.; Design: Double-blind randomized clinical trial.; Setting: Community.; Participants: Fifty-three individuals aged 60 and older with hypertension and executive dysfunction.; Intervention: Lisinopril, candesartan, or hydrochlorothiazide for 1 year.; Measurements: Cerebral blood flow velocity (BFV; transcranial […]